WINNIPEG, Dec. 17, 2019 /CNW/ - Waverley Pharma Inc.
("Waverley Pharma" or the "Company") (TSXV:WAVE), an emerging
Canadian pharmaceutical company, is pleased to announce that its
wholly-owned Irish subsidiary, Waverley Pharma Europe
Limited, has been granted marketing authorization in the
United Kingdom by the Medicines
& Healthcare products Regulatory Agency (MHRA) for three
different strengths of generic Erlotinib (25 mg, 100 mg and 150 mg
tablets). Erlotinib is an oral oncology medication used
to treat non-small cell lung cancer and pancreatic
cancer.
About Waverley Pharma
Waverley Pharma is an emerging pharmaceutical company focused on
the development and commercialization of safe, effective and
affordable cancer therapeutics in the EU and North American market.
The Company, through its subsidiary, is selling two generic
oncology products in the United
Kingdom, namely capecitabine and temozolomide and has three
additional generic products under development. Waverley Pharma is
committed to providing patients with affordable prescription
medicines that lower healthcare costs and provide a better quality
of life. For more information on Waverley Pharma please visit
www.waverleypharma.com.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Forward Looking Information: Statements
contained in this press release that are not statements of
historical fact, including, without limitation, statements
containing the words "believes", "may", "plans", "will",
"estimates", "continues", "anticipates", "intends", "expects" and
similar expressions, may constitute "forward-looking information"
within the meaning of applicable Canadian and U.S. federal
securities laws (such forward-looking information and
forward-looking statements are hereinafter collectively referred to
as "forward-looking statements"). Forward-looking statements and
other estimates, analysis and opinions of management of the Company
made in light of its experience and its perception of trends,
current conditions and expected developments, as well as other
factors which the Company believes to be relevant and reasonable in
the circumstances. Inherent in forward-looking statements are known
and unknown risks, uncertainties and other factors beyond the
Company's ability to predict or control that may cause the actual
results, events or developments to be materially different from any
future results, events or developments expressed or implied by such
forward-looking statements, and as such, readers are cautioned not
to place undue reliance on forward-looking statements. Such risk
factors include, among others, the Company's potential product
revenues, stage of development, additional capital requirements,
risks associated with the completion and timing of clinical trials
and obtaining regulatory approval to market the Company's products,
the ability to protect its intellectual property, dependence upon
collaborative partners, changes in government regulation or
regulatory approval processes, and rapid technological change in
the industry. Such statements are based on a number of assumptions
which may prove to be incorrect, including, but not limited to,
assumptions about: general business and economic conditions; the
impact of changes in Canadian-US dollar and other foreign exchange
rates on the Company's revenues, costs and results; the timing of
the receipt of regulatory and governmental approvals for the
Company's research and development projects; the availability of
financing for the Company's commercial operations and/or research
and development projects, or the availability of financing on
reasonable terms; the uncertainties associated with the acceptance
and demand for new products and market competition. The foregoing
list of important factors and assumptions is not exhaustive. The
Company undertakes no obligation to update publicly or otherwise
revise any forward-looking statements or the foregoing list of
factors, other than as may be required by applicable legislation.
Additional discussion regarding the risks and uncertainties
relating to the Company and its business can be found in the
Company's other filings with the applicable Canadian securities
regulatory authorities.
SOURCE Waverley Pharma Inc.